Azithromycin SR + Amoxiclav
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Community-Acquired Pneumonia
Conditions
Community-Acquired Pneumonia
Trial Timeline
Apr 1, 2010 → Dec 1, 2010
NCT ID
NCT01032694About Azithromycin SR + Amoxiclav
Azithromycin SR + Amoxiclav is a pre-clinical stage product being developed by Pfizer for Community-Acquired Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01032694. Target conditions include Community-Acquired Pneumonia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01032694 | Pre-clinical | Terminated |
Competing Products
9 competing products in Community-Acquired Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONO-5046Na + ONO-5046Na | Ono Pharmaceutical | Phase 2 | 52 |
| Ceftaroline + Ceftriaxone | Pfizer | Phase 3 | 76 |
| Azithromycin microspheres 2.0 single dose | Pfizer | Phase 3 | 76 |
| IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin | Pfizer | Approved | 84 |
| Azithromycin SR | Pfizer | Phase 3 | 76 |
| tigecycline | Pfizer | Phase 3 | 76 |
| Tigecycline + Levofloxacin | Pfizer | Phase 3 | 76 |
| Omadacycline + Moxifloxacin | Zai Lab | Phase 3 | 72 |
| ceftobiprole medocaril + IV standard-of-care cephalosporin | Basilea Pharmaceutica | Phase 3 | 72 |